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Clinical events at two-year follow-up
SES Endeavor
p-
value SES Resolute
p-
value
(n51) (n46) (n103) (n104)
Target lesion
revascularization,
n (%)
5 (9.8) 8 (17.4) 0.43 7 (6.8) 5 (4.8) 0.75
Target vessel
failure, n (%)†
6 (11.8) 8 (17.4) 0.62 7 (6.8) 7 (6.7) 0.73
Composite of
cardiac death
and MI, n (%)
1 (2.0) 2 (4.3) 0.60 0 2 (1.9) 0.49
Definite or
probable stent
thrombosis,
n (%)
1 (2.0) 2 (4.3) 0.60 0 1 (0.9) 1.00
According to the ARC criteria.
†Composite of cardiac death, myocardial infarctions (MI) and target vessel
revascularization.
Conclusions: Our study data indicate that the worse performance of Endeavor ZES
relative to SES in terms of late lumen loss, might translate in more clinical events. In
contrast, SES and Resolute ZES both show excellent angiographic outcome resulting in
comparable low clinical event rates after two years in patients treated for total coronary
occlusions.
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Background: Enhancement of coronary antegrade collateral vessels represents a poten-
tially novel therapeutic option for the treatment of chronic total occlusions (CTO). We
have investigated two prolyl-hydroxylase inhibitors (PHI) for their ability to stimulate
endothelial angiogenesis via upregulation of hypoxia inducible factor. We previously
reported that di-methyl oxalylglycine (DMOG) increased collateral neovascularisation in
a porcine CTO model. We now describe the actions of FG-2216, another PHI which
unlike DMOG has been previously used in anaemic renal patients.
Methods: Low passage (p3) human umbilical vein endothelial cells (HUVECs) were
cultured on growth factor reduced Matrigel in the presence of FG-2216 at a range of doses
(from 0 to 500M). Endothelial cell (EC) tubule formation was measured at 6 hours by
image analysis of photomicrographs (image J).
Results: Compared to control, ECs treated with FG-2216 demonstrated an enhanced
tubule formation on Matrigel with the number of internal loops formed by branching
tubules increasing with dose, up to 500M (20.56 (0M) versus 107.3 (500M), p0.05)
(Figure).
Conclusions: A proportion of CTOs cannot be revascularised by conventional means and
therapeutic enhancement of the collateral circulation may offer a novel approach. We have
demonstrated increased tubule formation in primary human ECs in response to FG-2216.
This novel proof of concept study represents a significant step towards the development
of therapeutic angiogenesis. We are collecting mechanistic data to confirm the action of
FG-2216 and will test its use as a stent-based therapy in models of CTO.
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Background: There is evidence that clopidogrel nonresponsivenss is a strong marker of
poor outcome in patients with coronary artery disease treated invasively. No data exist
about the impact of high residual platelet reactivity (HRPR) after 600 mg clopidogrel
loading on long-term clinical outcome in patients undergoing drug-eluting stent (DES)
implantation for chronic total occlusion (CTO).
Methods: The Florence CTO-PCI registry include consecutive patients treated for at least
1 CTO by DES supported percutaneous coronary intervention (PCI). Patients had
prospective platelet reactivity assessment by light transmittance aggregometry after a
loading dose of 600 mg of clopidogrel and using adenosine 5’-diphosphate (ADP) as
agonist. HRPR was defined as aggregation by 10 mol/L ADP 70. Clopidogrel therapy
75 mg daily was recommended for at least 1 year. The end point of the study was
long-term cardiac mortality. Cardiac survival was assessed by Kaplan-Meier estimation
and independent predictors of cardiac mortality were evaluated by forward stepwise Cox
regression analysis.
Results: From 2005 to 2010, 713 consecutive patients underwent CTO PCI and had “in
vitro” platelet reactivity assessment. A successful PCI was achieved in 569 patients
(80%). The incidence of HRPR after clopidogrel loading was 18%. There were no
significant differences in baseline characteristics between patients with HRPR and patients
with low residual platelet reactivity (LRPR). Successful CTO-PCI rates were similar
between groups (76% vs. 81%). The 2-year cardiac survival rate was 98  1% in the
LRPR group and 79  7% in the HRPR group (p0.001). By multivariable analysis,
HRPR resulted as a independent predictor of cardiac death (HR 3.0; p0.007); the others
variables related to cardiac death were age (HR 1.1; p0.001), left ventricular ejection
fraction  0.40 (HR 6.8; p0.001) and diabetes (HR 2.4; p0.033).
Conclusions: HRPR after clopidogrel loading is a strong prognostic marker of increased
risk of cardiac death in patients undergoing PCI for CTO.
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Background: Large registries have shown a survival benefit in patients with successful
chronic total occlusion (CTO)-PCI as compared to unsuccessful and/or unattempted
CTO-PCI. Sustained vessel patency may be considered as a main variable related to
long-term survival. Few data exist about the angiographic outcome of patients who
performed CTO-PCI, due to lack or very low angiographic follow-up rate of CTO
registries. The aim of this study was to assess the incidence of reocclusion and
identifications of predictors of angiographic failure after successful CTO-PCI in the
drug-eluting stent (DES) era.
Methods: From the large prospective Florence CTO-PCI registry, since 2004 to 2010,
1005 patients underwent a PCI for CTO (3 months). The protocol treatment includes
routine 6- to 9-month angiographic FU. Clinical, angiographic, and procedural variables
were included into the model of multivariable binary logistic regression analysis for the
identification of the predictors of reocclusion.
Results: From January 2004 to December 2010 1,005 patients underwent a PCI attempt
for at least 1 CTO (3 months). Out of these, 770 (77%) had a successful PCI. Baseline
and procedural characteristics: mean age 68  11, male 84%, diabetes 24%, previous
myocardial infarction 51%, LVEF0.40 37%, 3-vessel disease 50%, everolimus-eluting
stent (EES) 36%, stent lenght 40 mm 54%, long subintimal tracking and very distal
re-entry (STAR) 4%. STAR technique was used exclusively after failed intraluminal
anterograde or retrograde attempt. The angiographic FU rate was 80% (578 patients).
Reocclusion rate was 7.6%, while binary restenosis (50%) or reocclusion rate was 21%.
EES, was associated with a significant lower re-occlusion rate than other DES (2.4% vs.
9.9%; p0.001). A successful STAR technique was associated with a 55% of rocclusion
rate (p0.001). At multivariable analysis STAR technique (OR 32; p0.001) and EES
(OR 0.19; p0.002) were independently related to the risk of reocclusion.
Conclusions: Successful EES supported CTO-PCI is associated with a very high patency
rate (97.6%). Successful STAR technique is associated with a very low mid-term patency
rate whatever the type of stent used.
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